Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Principal Investigator
Ging-Yuek Robin HsiungOverview
Body Locations and Systems
Alzheimer's DiseaseDisorders and Conditions
Alzheimer's DiseaseClinicalTrials.gov#
NCT02008357Status
RecruitingStudy Start/End
Nov 17, 2014 to Dec 31, 2020Locations
UBC HospitalName/Title
Benita Mudge, Research CoordinatorPhone
604-822-7990Email Address
benita.mudge@vch.caPurpose of Study
The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]).
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.